Health ❯ Healthcare ❯ Biotechnology

Cancer Treatment

Immunotherapy Cell Therapies mRNA Technology mRNA Therapeutics Cell Therapy Head and Neck Cancer Petosemtamab Trials Chemotherapy RIPTAC Therapeutics Clinical Trials HER2-targeted Therapy Nanotherapeutics CAR T Cell Therapy Therapeutic Vaccines

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

The deal would bring Halda’s RIPTAC technology plus prostate cancer pill HLD-0915 under J&J pending antitrust clearance.

Propanc Biopharma Lines Up Up to $100 Million From Hexstone to Launch Digital-Asset Treasury and Speed PRP Toward Trials

Tubulis Raises €308 Million Series C to Accelerate Lead Cancer ADC

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Kite Pharma to Buy Interius for $350 Million, Adding In‑Vivo CAR‑T Platform